Abstract:Background and aims: Hepatic lipogenesis is elevated in nutrient abundant conditions to convert the excess carbohydrate into triacylglycerol (TAG). Fatty acyl moiety of TAG is eventually transported into adipose tissues by very low density lipoprotein, leading to the accumulation of TAG as a preferred storage form of excess energy. Disruption of the balance between TAG clearance and synthesis leads to the accumulation of lipids in the liver, leading to the progression of non-alcoholic fatty liver disease (NAFLD) including non-alcoholic steatohepatitis. Protein arginine methyltransferase (PRMT) 6 has been linked to the various metabolic processes including hepatic gluconeogenesis, muscle atrophy and lipodystrophy in mouse models. However, the role of PRMT6 in the control of hepatic lipogenesis has not been elucidated to date. Methods: We assessed the interaction between PRMT6 and LXR alpha by using co-immunoprecipitation assay. The specific arginine residue of LXR alpha that is methylated by PRMT6 was assessed by LC-MS/MS assay and the functional consequences of LXR alpha methylation was explored by mSREBP-1c luciferase assay. The effect of PRMT6 on hepatic lipogenesis was assessed by adenovirus-mediated ectopic expression of PRMT6 or knockdown of PRMT6 via shRNA in hepatocytes. Finally, the role of PRMT6 in hepatic lipid metabolism in vivo was explored by either ectopic expression of LXR alpha mutant that is defective in PRMT6-mediated arginine methylation or knockdown of PRMT6 in liver. Results: We found that promoter activity of sterol regulatory element binding protein (SREBP) 1c is robustly activated by PRMT6. Interestingly, we demonstrated that PRMT6 binds to LXR alpha, a transcription factor for SREBP-1c, via its LXXLL motif, leading to the asymmetric dimethylation of an arginine residue and activation of this protein. Indeed, ectopic expression of PRMT6 in hepatocytes led to the enhanced expression of LXR alpha target genes in the lipogenic pathway. Conversely, genetic or pharmacological inhibition of PRMT6 diminished expression of lipogenic genes and the lipid accumulation in primary hepatocytes. Mechanistically, we found that asymmetric dimethylation of LXR alpha led to the dissociation of small heterodimer partner (SHP), a transcriptional co-inhibitor of this factor, resulting in the activation of LXR alpha-mediated transcriptional process. Finally, we showed that disruption of asymmetric dimethylation of LXR alpha in the liver led to the diminished expression of genes in the lipogenesis, resulting in the reduced hepatic lipid accumulation in high fat diet-fed mice in vivo. Conclusions: We showed that PRMT6 modulates LXR alpha activity by conferring asymmetric dimethylation of arginine 253, thus blocking SHP-mediated inhibition and promoting hepatic lipid accumulation. These results suggest that PRMT6 is critical in the control of lipid homeostasis by regulation of LXR alpha-mediated lipogenesis in the liver.

Identification of ABHD6 as a regulator of lysophosphatidylserines in the mammalian liver and kidneys

Selective blockade of the lyso-PS lipase ABHD12 stimulates immune responses in vivo

Metabolomics Annotates ABHD3 As a Physiologic Regulator of Medium-Chain Phospholipids

Lysophosphatidic Acid Signaling Via LPA6: A Negative Modulator of Developmental Oligodendrocyte Maturation

Regulation of Bile Acid Biosynthesis by Hepatocyte Nuclear Factor 4Α

A Host Lipase Detoxifies Bacterial Lipopolysaccharides in the Liver and Spleen

ABHD6 suppression promotes anti-inflammatory polarization of adipose tissue macrophages via 2-monoacylglycerol/PPAR signaling in obese mice

Therapeutic potential of targeting α/β-Hydrolase domain-containing 6 (ABHD6)

Lipidome profiling in advanced metabolic liver disease identifies phosphatidylserine synthase 1 as a regulator of hepatic lipoprotein metabolism

The lysophosphatidylserine receptor GPR 174 constrains regulatory T cell development and function

An acylated N-terminus and a conserved loop regulate the activity of the ABHD17 de-acylase

Lysophosphatidic acid metabolism and signaling in heart disease

Effects of diet and hyperlipidemia on levels and distribution of circulating lysophosphatidic acid

The loss of enzymatic activity of the PHARC‐associated lipase ABHD12 results in increased phagocytosis that causes neuroinflammation

Lipid droplet-associated hydrolase mobilizes stores of liver X receptor sterol ligands and protects against atherosclerosis

Alpha/Beta-Hydrolase Domain-Containing 6: Signaling and Function in the Central Nervous System

Abstract 4113300: Targeting Liver Epsins Ameliorates Dyslipidemia in Atherosclerosis

Functional Characterization of Two Alpha Beta Hydrolase Domain (ABHD) Genes Associated with Lipid Accumulation in Ctenopharyngodon Idella Kidney (CIK) Cells

Regulation of hepatic lipogenesis by asymmetric arginine methylation

Lipid Droplet Targeting of ABHD5 and PNPLA3 I148M is required to promote liver steatosis

Abstract 10096: Genetic Control of Lysosomal Dysfunction Reprograms Sterol Metabolism in Pulmonary Arterial Hypertension